克唑替尼序贯阿来替尼治疗ALK重排非小细胞肺癌的多中心回顾性队列研究
本研究回顾性分析了840例ALK重排非小细胞肺癌患者,比较克唑替尼序贯阿来替尼与一线阿来替尼的疗效。克唑替尼组联合至治疗失败时间显著长于阿来替尼组(34.4 vs 27.2个月,HR 0.709,P=0.0044),但两组总生存无显著差异。
要点
- 克唑替尼序贯阿来替尼的联合TTF显著优于一线阿来替尼。
- 序贯治疗与一线阿来替尼的总生存无显著差异。
- 全人群中克唑替尼组总生存显著短于阿来替尼组。
核心结论
- 克唑替尼序贯阿来替尼的联合TTF显著长于一线阿来替尼,但未显示总生存获益。
研究设计与样本
- 多中心回顾性队列研究,纳入2012年5月至2016年12月接受克唑替尼或阿来替尼治疗的ALK重排非小细胞肺癌患者。
- 来自61家机构共864例患者入组,840例纳入分析;克唑替尼组535例,阿来替尼组305例。
主要发现
- 克唑替尼组联合TTF中位34.4个月,阿来替尼组TTF中位27.2个月,HR 0.709,P=0.0044。
- 克唑替尼序贯阿来替尼患者与一线阿来替尼患者的总生存无显著差异(中位88.4个月 vs 未达到,HR 1.048,P=0.7770)。
- 全人群中克唑替尼组总生存显著短于阿来替尼组(中位53.6个月 vs 未达到,HR 1.821,P<0.0001)。
临床怎么用
- 克唑替尼序贯阿来替尼可延长联合治疗失败时间,但未转化为总生存优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The data of sequential therapy of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in clinical practice have been limited. METHODS: We reviewed the clinical data of patients with ALK-rearranged non-small cell lung cancer who received crizotinib (CRZ) or alectinib (ALEC) between May 2012 and December 2016. Patients were divided into two groups based on the first-administered ALK-TKI, the CRZ or ALEC group. The combined time-to-treatment failure (TTF) was defined as the sum of the 'TTF of CRZ' plus the 'TTF of ALEC' if patients were treated with CRZ followed by ALEC in the CRZ group. The primary end-point is the comparison between the combined TTF and the TTF of ALEC in the ALEC group. RESULTS: Of 864 patients enrolled from 61 institutions, 840 patients were analysed. There were 535 of 305 patients in the CRZ/ALEC groups. The combined TTF in the CRZ group was significantly longer than TTF in the ALEC group (median, 34.4 versus 27.2 months; hazard ratio [HR], 0.709; P = 0.0044). However, there was no significant difference in overall survival (OS) between the patients who received ALEC after CRZ in the CRZ group and the patients in the ALEC group (median, 88.4 months versus. not reached; HR, 1.048; P = 0.7770). In the whole population, the CRZ group had a significantly shorter OS than the ALEC group (median, 53.6 months versus not reached; HR, 1.821, P < 0.0001). CONCLUSION: The combined TTF in the CRZ group was significantly longer than the TTF in the ALEC group; however, OS benefit of sequential therapy against ALEC as the first ALK-TKI was not shown.
引用
- Ito K, Yamanaka T, Hayashi H, et al. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. Eur J Cancer. 2021. PMID: 33486442. doi:10.1016/j.ejca.2020.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。